Anti-Bacillus anthracis pagA/Protective antigen/PAD4 Reference Antibody (Obiltoxaximab, RUO) (JN898016)

Name: Anti-Bacillus anthracis pagA/Protective antigen/PAD4 Reference Antibody (Obiltoxaximab, RUO)
Brand: abinScience
SKU: JN898016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	JN898016
Description	Obiltoxaximab (JN898016) is a research-grade recombinant antibody targeting Protective antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Bacillus anthracis
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Chimeric
Clonalité	Monoclonal
Isotype	IgG1-kappa
Système d'expression	Mammalian cells
Cible	Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P13423
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	ETI-204, 1351337-07-9
Contexte	Protective antigen (PA/pagA) is a ~85 kDa protein. Protective antigen constitutes one of the three proteins composing the anthrax toxin; it mediates attachment to host cells and translocation of edema factor (EF) and lethal factor (LF) into the host cytoplasm. PA associated with LF forms the lethal toxin (LeTx) and causes death when injected; PA associated with EF forms the edema toxin (EdTx) and produces edema. PA induces immunity to infection with anthrax. 1. Bradley, KA. et al. (2001) Nature 414, 225-9. PMID: 11700562 2. Bradley, KA. et al. (2003) The Journal of biological chemistry 278, 49342-7. PMID: 14507921 3. Santelli, E. et al. (2004) Nature 430, 905-8. PMID: 15243628 4. Lacy, DB. et al. (2004) Proceedings of the National Academy of Sciences of the United States of America 101, 13147-51. PMID: 15326297 5. Singh, Y. et al. (1991) The Journal of biological chemistry 266, 15493-7. PMID: 1651334 6. Mock, M. et al. (2001) Annual review of microbiology 55, 647-71. PMID: 11544370
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SEC-HPLC

SEC-HPLC detection for Research Grade Obiltoxaximab.
Bioactivity

Detects PA/pagA/PA-83 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Obiltoxaximab
Western blot

Western blot analysis was performed using anti-PA/pagA/PA-83 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 50ng
Lane 2: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 30ng
Lane 3: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 20ng
Lane 4: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 10ng